UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

November 410, 2025

Date of Report (Date of earliest event reported)

CervoMed Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37942	30-0645032
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

20 Park Plaza, Suite 424 Boston, Massachusetts		02116
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 744-4400

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CRVO		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 72.0102 ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition

~~Press~~On ~~Release~~November 10, 2025, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended September 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

OnThe ~~November~~information 4,included ~~2025,~~in ~~CervoMed~~or ~~Inc~~incorporated by reference into this Item 2.02 (~~the~~including ~~“Company”~~Exhibit 99.1) ~~issued~~is abeing ~~press~~furnished ~~release~~pursuant ~~announcing~~to ~~that~~Item it2.02 ~~had~~of ~~received~~Form ~~written~~8-K ~~feedback~~and ~~from~~shall ~~the~~not ~~U.S.~~be ~~Food~~deemed ~~and~~to ~~Drug~~be ~~Administration~~“filed” ~~aligning~~for onpurposes ~~key~~of ~~aspects~~Section 18 of the ~~Company’s~~Exchange ~~proposed~~Act, ~~Phase~~or 3otherwise ~~clinical~~subject ~~trial~~to ofthe ~~neflamapimod~~liabilities inof ~~patients~~that ~~with~~section, ~~dementia~~nor ~~with~~shall ~~Lewy~~it ~~bodies.~~be Adeemed ~~copy~~to ofbe ~~the~~incorporated ~~press~~by ~~release~~reference isin ~~attached~~any ~~hereto~~filing asunder ~~Exhibit~~the ~~99.1~~Securities ~~and~~Act ~~incorporated~~or bythe ~~reference~~Exchange ~~herein~~Act.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events

The information set forth in the first paragraph, the information set forth under the heading “Phase 3 Trial Design and Regulatory Alignment,” and the information set forth in the second paragraph under the heading “Advancing Towards Registration” of the Company’s press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 7.01 is furnished and not filed:

Exhibit No.	Description

99.1	Press Release, issued November 10, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

Exhibit No.	Description
99.1	Press Release, issued November 4, 2025.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 4, 2025	CervoMed Inc.
Date: November 10, 2025	CervoMed Inc.
	By:	/s/ William Elder
	Name:	William Elder
	Title:	Chief Financial Officer & General Counsel

Filing Compare · CervoMed Inc.